Specialty Pharmacy Accreditation Landscape 2025: What DCI's Market Analysis Means for Distributors

The specialty pharmacy accreditation market reached 4,311 active accreditations in 2024, according to Drug Channels Institute's February 2025 market analysis. Wholesale drug distributors serving specialty pharmacies now face stricter partnership qualification requirements as accreditation becomes a de facto prerequisite for high-value distribution relationships, particularly in oncology, rare disease, and manufacturer-direct specialty products.

Regulatory Context: Accreditation vs. Licensure

Specialty pharmacy accreditation operates separately from state wholesale drug distributor licensing requirements. While all pharmacies must hold state pharmacy licenses under each jurisdiction's pharmacy practice act, specialty pharmacy accreditation is a voluntary private-sector credentialing process. The three dominant accreditation bodies—URAC (Utilization Review Accreditation Commission), ACHC (Accreditation Commission for Health Care), and The Joint Commission—each maintain distinct specialty pharmacy standards focused on clinical services, medication management protocols, and patient support programs that extend beyond basic pharmacy licensure requirements.

Unlike state licensure, which pharmaceutical distributors verify through state boards of pharmacy, specialty pharmacy accreditation requires cross-referencing three separate accreditation databases. URAC maintains approximately 1,600 specialty pharmacy accreditations as of Q1 2025. ACHC holds roughly 1,200 specialty pharmacy accreditations. The Joint Commission accounts for the remaining accreditations in DCI's 4,311 total. No federal statute mandates specialty pharmacy accreditation, but payer contracts and manufacturer-direct distribution agreements increasingly require URAC or ACHC certification as a contracting prerequisite.

DCI's Key Findings: Market Concentration and Accreditation Growth

DCI's analysis shows specialty pharmacy accreditation concentrated among three pharmacy types: independent specialty pharmacies (52% of accredited entities), health system-affiliated specialty pharmacies (31%), and manufacturer-owned specialty pharmacies (11%). The remaining 6% includes retail chain specialty divisions and mail-order specialty pharmacy operations.

Year-over-year growth in specialty pharmacy accreditation reached 8.3% between 2023 and 2024, driven primarily by payer contract requirements and specialty drug manufacturer distribution policies. URAC specialty pharmacy accreditation requirements now appear in 73% of commercial payer specialty pharmacy network agreements, per DCI's payer contract analysis. ACHC specialty pharmacy standards dominate in oncology and infusion therapy specialty segments, appearing in 68% of oncology buy-and-bill distribution agreements.

The accreditation requirement gap creates distribution compliance risk. Approximately 2,100 specialty pharmacies operate without third-party accreditation, relying solely on state licensure. These entities face limited access to specialty drug distribution channels as manufacturers implement tighter specialty pharmacy network controls under REMS (Risk Evaluation and Mitigation Strategy) programs and limited distribution networks.

Distribution Partnership Implications

Wholesale drug distributors conducting specialty pharmacy due diligence must now verify accreditation status across multiple databases. State pharmacy license verification alone no longer satisfies manufacturer distribution compliance requirements for specialty products. McKesson's CoverMyMeds specialty pharmacy network, for example, requires URAC or ACHC accreditation for oncology and rare disease product access. AmerisourceBergen's Oncology Connect program mandates ACHC specialty pharmacy accreditation or GPO-equivalent credentialing.

The compliance burden shifts to distributors serving non-accredited specialty pharmacies. A distributor fulfilling orders from a specialty pharmacy lacking URAC or ACHC credentials risks product diversion allegations if the pharmacy falls outside manufacturer-approved distribution networks. Under DSCSA trading partner verification requirements (21 USC 360eee-1), distributors must verify that the receiving pharmacy is an "authorized trading partner"—a definition increasingly interpreted by manufacturers to include accreditation requirements beyond state licensure.

Distribution agreements now incorporate specialty pharmacy compliance requirements. 3PLs handling manufacturer-direct specialty product logistics face contractual obligations to verify pharmacy accreditation before shipment release. Cold chain logistics providers storing specialty biologics must confirm that destination pharmacies meet manufacturer-specified accreditation standards to maintain GDP (Good Distribution Practice) compliance under their third-party logistics licenses.

What ColdChainCheck Data Shows

ColdChainCheck currently tracks 1,275 wholesale drug distributors and 3PLs, of which 63 hold NABP accreditation (VAWD or LegitScript certification). The directory does not yet include specialty pharmacy accreditation data from URAC, ACHC, or The Joint Commission—these accreditation programs credential pharmacies, not wholesale distributors. However, the compliance framework overlap matters: distributors serving specialty pharmacies must verify their trading partners' accreditation status using the same cross-referencing methodology ColdChainCheck applies to wholesale distributor licensing.

The average compliance score across tracked entities stands at 51/100, placing most distributors in the "Fair" tier (919 entities). Only 28 entities score in the "Excellent" range (76-100 points), indicating comprehensive verification across state licensure, FDA registration, and NABP accreditation. For distributors establishing specialty pharmacy distribution partnerships, this score distribution suggests that most entities maintain baseline regulatory compliance (state licenses, FDA registration) but lack the enhanced accreditation signals increasingly required in specialty drug supply chains.

73 entities in the directory carry at least one FDA recall on record. While recalls primarily reflect product quality issues rather than distribution compliance failures, specialty drug manufacturers conducting distributor due diligence increasingly weight enforcement history in network qualification decisions. A distributor with a recall history faces heightened scrutiny when applying for manufacturer-direct specialty product distribution agreements.

Practical Guidance for Compliance Teams

• Verify specialty pharmacy trading partners separately from distributor verification. ColdChainCheck's wholesale distributor compliance data does not substitute for specialty pharmacy accreditation verification. Cross-reference URAC's directory (urac.org), ACHC's searchable database (achc.org), and The Joint Commission's Quality Check tool (qualitycheck.org) before approving a specialty pharmacy as an authorized trading partner.

• Document the accreditation gap in risk assessments. If your distribution network includes non-accredited specialty pharmacies, document the risk mitigation plan in your DSCSA compliance file. State pharmacy licensure alone may not satisfy manufacturer-direct distribution agreement requirements. Use ColdChainCheck's directory to cross-reference your existing wholesale partners' compliance posture as a due diligence baseline.

• Monitor manufacturer distribution policy changes. Specialty drug manufacturers update limited distribution network criteria quarterly. A specialty pharmacy accredited today may lose credentials or face additional requirements under revised REMS protocols. Track NABP accreditation status for your wholesale partners using ColdChainCheck's monitoring system, then apply the same tracking discipline to specialty pharmacy accreditation renewals.

• Flag 3PL contracts handling specialty products. If your organization uses third-party logistics providers for specialty drug storage or distribution, confirm that 3PL agreements include specialty pharmacy accreditation verification obligations. Review tracked 3PLs in ColdChainCheck's directory to identify entities scoring below 60/100, then prioritize contract amendments requiring trading partner accreditation checks before specialty product shipment release.

ColdChainCheck tracks wholesale distributor compliance signals across state licensure, FDA registration, NABP accreditation, and enforcement history. Specialty pharmacy accreditation data remains outside the current directory scope but follows the same verification principles: cross-reference multiple authoritative sources, document verification dates, and re-verify on a defined cadence. See ColdChainCheck's DSCSA compliance checklist for additional coverage of trading partner verification requirements and wholesale distributor due diligence workflows.

Disclaimer: This article provides informational analysis of specialty pharmacy accreditation market trends and their implications for pharmaceutical distribution partnerships. It does not constitute legal or regulatory advice. Verify all accreditation requirements with the relevant accrediting bodies, manufacturer distribution agreements, and legal counsel before making distribution partnership decisions.